## axinn

# Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson's Abiraterone Drug For Prostate Cancer

NEWS | 1 MIN READ

November 29, 2010

PharmaWire reported on November 29, 2010 that the patent life of BTG and Johnson & Johnson's potential prostate cancer blockbuster abiraterone is unclear due to laws changed in 1995 for calculating expiration dates. According to BTG, abiraterone is protected until 2024. Although abiraterone is a simple molecule that will be reproduced by generic companies very easily and the drug may have a short patent life relying on data exclusivity, experts believe the data is still striking enough to secure a large market share in this timeframe. The companies are expected to also file for an extension of the patent for up to five years. However, patents covering manufacturing and synthesis methods typically cannot be enforced against generic applicants until shortly prior to commercial launch, Matthew Becker, a patent attorney at Axinn, noted in the article.

### **Related People**



Matthew J. Becker

#### **Related Services**

Intellectual Property

To subscribe to our publications, click here.

#### **Featured Insights**

- NJSBA Annual Meeting and Convention 2025
   SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- CompLaw Antitrust West Coast Conference 2025
   SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
   SPONSORSHIP ANTITRUST
- IAM Live: Auto IP USA 2025

  SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- ACI 21st Annual Paragraph IV Conference
   SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- ABA 73rd Annual Section of Antitrust Law Spring Meeting SPEAKING ENGAGEMENT ANTITRUST
- AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice SPEAKING ENGAGEMENT
- Axinn Wins at 2025 Global Competition Review Awards
   AWARDS & RECOGNITIONS ANTITRUST
- Committed to Excellence: Axinn Thought Leadership Recognized at the 2025 Concurrences Antitrust Writing Awards
   AWARDS & RECOGNITIONS ANTITRUST

| • | 17th Annual Practitioners | s' Think Tank on ITC Litigation & Enforcement |
|---|---------------------------|---|
|   | SPEAKING ENGAGEMENT       | INTELLECTUAL PROPERTY                         |

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved